LUND, Sweden, June 21, 2018 /PRNewswire/ --
Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will present additional preclinical data for
Growth Capitalist (https://growthcapitalist.com/2018/06/alligator-biosciences-ator-1017-strongly-activates-both-t-cells-and-nk-cells-important-for-the-effective-eradication-of-tumor-cells/)
LUND, Sweden, June 21, 2018 /PRNewswire/ --
Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will present additional preclinical data for